Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use

• Main Authors: Abate, M. (Author), Biondi, M. (Author), Campani, V. (Author), Caraglia, M. (Author), De Rosa, G. (Author), Leonetti, C. (Author), Nele, V. (Author), Porru, M. (Author), Scotti, L. (Author), Zappavigna, S. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: bisphosphonates; differential scanning calorimetry; glioblastoma; lyophilization; scale-up; self-assembling nanoparticles; zoledronic acid
• Online Access: View Fulltext in Publisher

 Self-assembling nanoparticles (SANPs) promise an effective delivery of bisphosphonates or microRNAs in the treatment of glioblastoma (GBM) and are obtained through the sequential mixing of four components immediately before use. The self-assembling approach facilitates technology transfer, but the complexity of the SANP preparation protocol raises significant concerns in the clinical setting due to the high risk of human errors during the procedure. In this work, it was hypothesized that the SANP preparation protocol could be simplified by using freeze-dried formulations. An in-depth thermodynamic study was conducted on solutions of different cryoprotectants, namely sucrose, mannitol and trehalose, to test their ability to stabilize the produced SANPs. In addition, the ability of SANPs to deliver drugs after lyophilization was assessed on selected formulations encapsulating zoledronic acid in vitro in the T98G GBM cell line and in vivo in an orthotopic mouse model. Results showed that, after lyophilization optimization, freeze-dried SANPs encapsulating zoledronic acid could retain their delivery ability, showing a significant inhibition of T98G cell growth both in vitro and in vivo. Overall, these results suggest that freeze-drying may help boost the industrial development of SANPs for the delivery of drugs to the brain. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.